What are S1P1 receptor antagonist drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

S1P1 receptor antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting S1P1 (Sphingosine-1-phosphate receptor 1)). 0 are currently marketed, with 4 more in clinical development.

S1P1 receptor antagonist

0 marketed 2 in Phase 3 2 in Phase 2

This page covers all S1P1 receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting S1P1 (Sphingosine-1-phosphate receptor 1), S1P1.

Targets

S1P1 (Sphingosine-1-phosphate receptor 1) · S1P1

Phase 3 pipeline (2)

SPM 907 · Pfizer · Immunology
SPM 907 is a selective antagonist of the S1P1 receptor that reduces lymphocyte egress from lymphoid tissues, thereby decreasing circulating lymphocyte counts.
JYB1904 · Jemincare · Autoimmune diseases
JYB1904 is a small molecule targeting the S1P1 receptor.

Phase 2 pipeline (2)

ABBV-CLS-628 · AbbVie · Autoimmune diseases
ABBV-CLS-628 is a small molecule targeting the S1P1 receptor.
ATS907 · Altheos, Inc. · Autoimmune diseases
ATS907 is a small molecule that targets the S1P1 receptor.

Patent intelligence

s1p1 receptor antagonist patent landscape — aggregated cliff calendar, attackable patents, originator estates